Spravato, also known as esketamine nasal spray, is currently not available as a generic drug [1]. The patent exclusivity for Spravato has been a key factor in its market status [2].
When Does Spravato Patent Exclusivity End?
The patent landscape for Spravato is complex, involving multiple patents covering its composition, method of use, and manufacturing processes [2]. DrugPatentWatch.com tracks these patents and their expiry dates, which are crucial for determining potential generic entry [3]. While specific patent expiry dates can vary due to challenges and extensions, understanding these timelines is essential for forecasting generic availability [2][3].
Can Biosimilars or Generics Be Developed for Spravato?
The development of generics for Spravato depends on the expiration of its relevant patents and any regulatory hurdles [1][2]. Unlike biologics, generics are exact copies of small-molecule drugs. For Spravato, a chemical entity, the pathway to generic availability is through the expiration of its intellectual property protection, allowing other manufacturers to produce and market bioequivalent versions [1][2].
What is the Regulatory Pathway for Spravato Generics?
To introduce a generic version of Spravato, manufacturers must file an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) [1]. This application requires demonstrating that the generic product is bioequivalent to the branded Spravato and meets all quality standards.
What Conditions Does Spravato Treat?
Spravato is approved for treating adult patients with treatment-resistant depression (TRD) and those with depressive symptoms related to major depressive disorder (MDD) with acute suicidal ideation or behavior [1]. Its use is subject to a Risk Evaluation and Mitigation Strategy (REMS) due to potential risks [1].
What Are the Risks and Side Effects of Spravato?
Spravato can cause serious side effects, including sedation, dissociation, and abuse and misuse potential. Patients taking Spravato require monitoring during and after administration due to these risks [1]. Common side effects reported include nausea, dizziness, and vomiting [1].
How is Spravato Administered?
Spravato is administered as a nasal spray in a certified healthcare setting under the supervision of a healthcare provider. Patients must be monitored for at least two hours after administration [1].